FDA Grants Priority Review to Tovorafenib in Pediatric Relap

The FDA has granted priority review to a new drug application seeking the approval of tovorafenib monotherapy for the treatment of pediatric patients with relapsed or progressive low-grade glioma.

Related Keywords

Jeremy Bender , , Response Assessment , Prescription Drug User Fee Act , Day One Biopharmaceuticals , Pediatric Neuro Oncology , Low Grade Glioma , Pediatric Low Grade Glioma , Fda , Priority Review , Tovorafenib ,